Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Laplaud

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 1, 2022
Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis societySandra Vukusic, Clarisse Carra-Dalliere, Jonathan Ciron, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 18, 2025
Pregnancy and birth outcomes in women with multiple sclerosis: Comparison of the RESPONSE study to the general French populationElisabeth Maillart, Fabien Rollot, Emmanuelle Leray, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 8, 2022
Pregnancy and neuromyelitis optica spectrum disorders: 2022 recommendations from the French Multiple Sclerosis SocietySandra Vukusic, Romain Marignier, Jonathan Ciron, et al.
European Journal of Neurology|March 2, 2021
Untreated patients with multiple sclerosis: A study of French expert centersXavier Moisset, Audrey-Anne Fouchard, Bruno Pereira, et al.
JAMA Network Open|October 11, 2021
Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated SyndromeChristine Lebrun-Frénay, Fabien Rollot, Lydiane Mondot, et al.
The Journal of Clinical Investigation|October 19, 2020
Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistanceVanessa Gauttier, Sabrina Pengam, Justine Durand, et al.
European Journal of Neurology|May 2, 2025
Secondary progression activity monitoring in MS despite an early highly active treatment the SPAM studyMikael Cohen, Fabien Rollot, Marc Debouverie, et al.
Multiple Sclerosis and Related Disorders|July 7, 2020
Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patientsDaniel H Whittam, Alvaro Cobo-Calvo, A Sebastian Lopez-Chiriboga, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 11, 2021
Determinants of therapeutic lag in multiple sclerosisIzanne Roos, Emmanuelle Leray, Federico Frascoli, et al.
CNS Drugs|September 18, 2021
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Mathilde Lefort, Johanna Balslev Andersen, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 1, 2022
Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis societySandra Vukusic, Clarisse Carra-Dalliere, Jonathan Ciron, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 18, 2025
Pregnancy and birth outcomes in women with multiple sclerosis: Comparison of the RESPONSE study to the general French populationElisabeth Maillart, Fabien Rollot, Emmanuelle Leray, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 8, 2022
Pregnancy and neuromyelitis optica spectrum disorders: 2022 recommendations from the French Multiple Sclerosis SocietySandra Vukusic, Romain Marignier, Jonathan Ciron, et al.
European Journal of Neurology|March 2, 2021
Untreated patients with multiple sclerosis: A study of French expert centersXavier Moisset, Audrey-Anne Fouchard, Bruno Pereira, et al.
JAMA Network Open|October 11, 2021
Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated SyndromeChristine Lebrun-Frénay, Fabien Rollot, Lydiane Mondot, et al.
The Journal of Clinical Investigation|October 19, 2020
Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistanceVanessa Gauttier, Sabrina Pengam, Justine Durand, et al.
European Journal of Neurology|May 2, 2025
Secondary progression activity monitoring in MS despite an early highly active treatment the SPAM studyMikael Cohen, Fabien Rollot, Marc Debouverie, et al.
Multiple Sclerosis and Related Disorders|July 7, 2020
Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patientsDaniel H Whittam, Alvaro Cobo-Calvo, A Sebastian Lopez-Chiriboga, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 11, 2021
Determinants of therapeutic lag in multiple sclerosisIzanne Roos, Emmanuelle Leray, Federico Frascoli, et al.
CNS Drugs|September 18, 2021
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Mathilde Lefort, Johanna Balslev Andersen, et al.
Pageof 6